patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis
Published 9 years ago • 455 plays • Length 3:15Download video MP4
Download video MP3
Similar videos
-
1:36
dr. coleman discusses the toxicities associated with rucaparib in patients with ovarian cancer
-
1:21
rucaparib may improve pfs in patients with ovarian cancer
-
4:25
rucaparib: clinical activity in relapsed ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
5:11
defining rucaparib’s value in recurrent ovarian cancer
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer
-
4:02
initial impressions of a patient with ovarian cancer
-
1:07:06
genetic testing can save lives
-
5:17
outlook for patients with high-risk ovarian cancer
-
1:59
dr. coleman on next steps following ariel2 trial for ovarian cancer
-
28:57
2021 force | hereditary cancer | cancer risks, screening & prevention for brca1 or brca2 mutations
-
4:24
gene testing and treatment for recurrent ovarian cancer
-
3:34
aacr 2011: ovarian cancer patients with brca mutations show improved survival.
-
1:29
significant factors of clinical outcomes with olaparib in patients with ovarian cancer
-
3:25
ovarian cancer: recurrence after parp inhibition
-
3:42
gynecologic oncology at asco 2022: athena–mono trial (rucaparib monotherapy) for ovarian cancer
-
2:16
biomarker for parp inhibitor responsiveness in ovarian cancer patients
-
3:10
genetic testing and frontline therapy in ovarian cancer
-
4:39
recurrent ovarian cancer: third-line therapy and beyond